Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Allergy & Immunology
•
Mastocytosis
•
Mast Cell Disorders
Does a patient with known systemic mastocytosis need a bone biopsy of lytic vertebral lesions to rule out other etiologies?
Related Questions
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell activation syndrome besides omalizumab?
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
Have you experienced any issues with Alvesco inhalers getting clogged repeatedly?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
